Pharmaceuticals
CStone successfully hosted the first U.S. R&D Day in New York
* Among CStone's 15 cancer drug candidates, five candidates are in pivotal late-stage clinical development, with a total of 13 on-going registrational trials. * The Company has implemented its pipeline strategy for early-stage candidates and combination therapy. With an established clinical d...
2020-01-24 08:18
3888
CStone successfully hosted the first U.S. R&D Day in New York
* Among CStone's 15 cancer drug candidates, five candidates are in pivotal late-stage clinical development, with a total of 13 on-going registrational trials. * The Company has implemented its pipeline strategy for early-stage candidates and combination therapy. With an established clinical d...
2020-01-24 08:03
2574
Inovio Selected by CEPI to Develop Vaccine Against New Coronavirus
PLYMOUTH MEETING, Pa., Jan. 24, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the Coalition for Epidemic Preparedness Innovations (CEPI) has awarded Inovio a grant of up to$9 million to develop a vaccine against the recently emerged strain of coronavirus (2019-nCo...
2020-01-24 00:26
3996
Eddy Cojulun New Chief Sales Officer at Envirotainer
UPPLANDS VASBY, Sweden, Jan. 22, 2020 /PRNewswire/ -- Envirotainer, the global market leader in secure cold chain solutions for air transport of pharmaceuticals, today announced thatEddy Cojulun joined Envirotainer as the new Chief Sales Officer (CSO) inDecember 2019. In his new role Eddy will r...
2020-01-22 15:27
879
US Food and Drug Administration (FDA) grants priority review of belantamab mafodotin for patients with relapsed or refractory multiple myeloma
* Biologics License Application based on results from the pivotal DREAMM-2 study of immunoconjugate targeting B-cell maturation antigen (BCMA) in heavily pre-treated patient population who was refractory to an immunomodulatory drug and a proteasome inhibitor, and refractory or intolerant to an ...
2020-01-21 22:00
10647
TenNor Therapeutics Received FDA Orphan Drug Designation
SUZHOU, China, Jan. 20, 2020 /PRNewswire/ -- TenNor Therapeutics, a clinical-stage, global biopharmaceutical company has received FDA Orphan Drug Designation for TNP-2092 to treat prosthetic joint infections. Medical devices such as prosthetic joints, central venous catheters and artificial hear...
2020-01-20 20:50
966
Bridge Biotherapeutics Announces FDA IND Clearance for BBT-176, an EGFR TKI for NSCLC
SEONGNAM, South Korea, Jan. 19, 2020 /PRNewswire/ -- Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, Republic of Korea, announced that the Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration (FDA) has been cleared ...
2020-01-20 10:44
1222
QBiotics receives first registration for tigilanol tiglate with European Medicines Agency approval of Stelfonta(R)
* STELFONTA® (tigilanol tiglate) approved by the European Medicines Agency (EMA), making it the first pharmaceutical treatment available for all grades of canine non-metastatic mast cell tumours (MCT)[1] * The approval marks the first registration of QBiotic's, lead compound tigilanol tiglate...
2020-01-20 07:00
3377
111, Inc. Featured at 38th Annual JP Morgan Healthcare Conference
SHANGHAI, Jan. 17, 2020 /PRNewswire/ -- Junling Liu, co-founder, Chairman, and Chief Executive Officer of 111, Inc. (NASDAQ: YI) a leading integrated online and offline healthcare platform, gave an address entitled "Driving Transformation inChina's Healthcare and Pharmaceutical Industry" at the 3...
2020-01-17 20:00
7554
China SXT Pharmaceuticals, Inc. Announced Regulatory Approval of Its DNA Exam Laboratory
TAIZHOU, China, Jan. 16, 2020 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Ad...
2020-01-16 21:00
6146
WuXi Biologics and Bayer Enter into an Acquisition Agreement on a Drug Product Plant in Germany
* First drug product facility in Europe to complement WuXi Biologics' existing commercial manufacturing capacities * WuXi Biologics will be the back-up manufacturer for Kovaltry™ of Bayer SHANGHAI and LEVERKUSEN, Germany, Jan. 15, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a ...
2020-01-16 10:39
17963
FDF China to be held in June to boost Chinese pharmaceutical enterprises to "go global" and promote the innovation and development of industry
SHANGHAI, Jan. 16, 2020 /PRNewswire/ -- FDF China, collocated with CPhI China, will be held fromJune 22-24, 2020 at Shanghai New International Expo Centre (SNIEC). More and more formulation enterprises need to implement strategic layout to step up cooperation in innovation and facilitate the inte...
2020-01-16 09:52
2152
Hanmi Pharmaceutical participated in the 38th J.P. Morgan Healthcare Conference, announces that it is "ready to lead global pharmaceutical market with innovative R&D pipeline"
SEOUL, South Korea, Jan. 15, 2020 /PRNewswire/ -- The company, led by President and CEO Se-chang Kwon and co-representative Jong-soo Woo, participated in the 38th J.P. Morgan Healthcare Conference inSan Francisco during Jan. 13-15, which it presented its vision and major R&D strategies for 2020. ...
2020-01-16 07:30
1514
Genome & Company announces a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer
SEOUL, South Korea, Jan. 14, 2020 /PRNewswire/ -- Genome & Company (KONEX: 314130) is pleased to announce that it has entered into a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt,Germany and Pfizer Inc. to evaluate the safety, tolerability, biological and clinical ...
2020-01-14 08:00
3248
COMPASS Pathways Granted Patent Covering Use of Its Psilocybin Formulation in Addressing Treatment-resistant Depression
LONDON, Jan. 13, 2020 /PRNewswire/ -- COMPASS Pathways, a mental health care company, announced today that it has been granted US Patent No 10,519,175, relating to methods of treating drug-resistant depression with a psilocybin formulation, by the US Patent and Trademark Office. The patent covers...
2020-01-13 19:05
1137
Discover the Latest Information and Seize Market Opportunities in the Annual Event of the CRO & CMO Industry at ICSE China 2020
SHANGHAI, Jan. 13, 2020 /PRNewswire/ -- The ICSE China 2020 will take place in Hall E2, E3/E7 of Shanghai New International Expo Centre fromJune 22-24, 2020. It will gather Chinese and overseas pharmaceutical experts, showcase advanced products and technologies in the CRO & CMO area and explore f...
2020-01-13 17:34
2118
Nanoform Appoints Head of US Sales
HELSINKI, Jan. 13, 2020 /PRNewswire/ -- Nanoform, an innovative nanoparticle medicine enabling company, has appointedSally Langa as Head of US Sales. The new role will enable Nanoform to continue its rapid growth with a strengthened presence in the US market. As Head of US Sales, Sally Langa wil...
2020-01-13 15:21
1014
Tyvyt (Sintilimab Injection) Combined with ALIMTA (Pemetrexed) and Platinum Met Predefined Primary Endpoint in Phase 3 ORIENT-11 Study as First-Line Therapy in Nonsquamous NSCLC
SUZHOU, China, Jan. 13, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, today jointly announced...
2020-01-13 12:42
13748
Seneca Biopharma Announces Presentations at Both Sachs Associates 3rd Annual Neuroscience Innovation Forum & Biotech Showcase™ 2020
GERMANTOWN, Maryland, Jan. 10, 2020 /PRNewswire/ -- Seneca Biopharma, Inc., (NASDAQ: SNCA), a clinical-stage biopharmaceutical company developing novel treatments for diseases of unmet medical need, announced today thatSeneca's Executive Chairman,Ken Carter, will present at both Sachs Associates ...
2020-01-11 00:00
6631
WuXi Biologics and Almirall Sign Strategic Collaboration Agreement for Multiple Bispecific Antibodies Targeting Dermatology Diseases
* The 12th global licensing partnership for WuXiBody™ since its launch in August 2018 showcasing the power and versatile applications of WuXiBody™ in multiple therapeutic areas SHANGHAI and BARCELONA, Spain, Jan. 9, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global o...
2020-01-09 17:10
2635
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
5310
